Mycobacterium tuberculosis

Mycobacterium tuberculosis
Photo Credit: Content Providers(s): CDC/Dr. George Kubica · Public domain · source
Name	Mycobacterium tuberculosis
Domain	Bacteria
Phylum	Actinobacteria
Class	Actinobacteria
Order	Corynebacteriales
Family	Mycobacteriaceae
Genus	Mycobacterium
Species	M. tuberculosis

Mycobacterium tuberculosis is a species of pathogenic bacteria that causes tuberculosis (TB), a serious and sometimes life-threatening disease that primarily affects the lungs of humans, as described by Robert Koch and Louis Pasteur. The bacterium was first identified by Robert Koch in 1882, and since then, it has been the subject of extensive research by Scientists such as Alexander Fleming and Selman Waksman. World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) have been working together to combat the spread of TB, which affects millions of people worldwide, including those in Africa, Asia, and Europe. National Institute of Allergy and Infectious Diseases (NIAID) and Bill and Melinda Gates Foundation have also been supporting research on TB.

● Introduction

Mycobacterium tuberculosis is a member of the Mycobacteriaceae family, which includes other pathogenic species such as Mycobacterium leprae and Mycobacterium bovis. The bacterium is a facultative intracellular parasite that can survive and replicate within the cells of the immune system, including macrophages and dendritic cells, as studied by Albert Einstein and Marie Curie. University of Cambridge and Harvard University have been conducting research on the bacterium's ability to evade the host's immune response, which is mediated by cytokines such as interferon-gamma and tumor necrosis factor-alpha. Institut Pasteur and National Institutes of Health (NIH) have also been investigating the role of vaccines in preventing TB, including the BCG vaccine developed by Albert Calmette and Camille Guérin.

● Classification_and_Characteristics

Mycobacterium tuberculosis is a Gram-positive bacterium that is characterized by its unique cell wall composition, which includes mycolic acids and lipids such as trehalose dimycolate. The bacterium is also known for its slow growth rate, which makes it difficult to culture in the laboratory, as noted by Louis Pasteur and Robert Koch. University of Oxford and Stanford University have been studying the bacterium's genomics and proteomics to better understand its pathogenesis and develop new diagnostic tools, including PCR and sequencing techniques developed by Kary Mullis and Frederick Sanger. European Union and World Bank have been supporting research on TB, including the development of new drugs and vaccines.

● Pathogenesis

The pathogenesis of Mycobacterium tuberculosis involves the bacterium's ability to infect and replicate within the cells of the immune system, including macrophages and dendritic cells, as described by Alexander Fleming and Selman Waksman. The bacterium produces a range of virulence factors, including proteins and lipids, that help it to evade the host's immune response and establish a persistent infection, as studied by University of California, Berkeley and Massachusetts Institute of Technology (MIT). National Institute of Environmental Health Sciences (NIEHS) and Environmental Protection Agency (EPA) have been investigating the role of environmental factors in the development of TB, including air pollution and poverty. United Nations (UN) and Red Cross have been working to combat the spread of TB in developing countries.

● Diagnosis

The diagnosis of Mycobacterium tuberculosis infection typically involves a combination of clinical symptoms, radiographic imaging, and laboratory tests, including smear microscopy and culture, as developed by Robert Koch and Louis Pasteur. University of Chicago and Johns Hopkins University have been developing new diagnostic tools, including molecular diagnostics and point-of-care tests, to improve the detection of TB, particularly in resource-limited settings. Bill and Melinda Gates Foundation and WHO have been supporting the development of new diagnostic technologies, including rapid diagnostic tests and mobile health applications, as used in Africa and Asia.

● Treatment

The treatment of Mycobacterium tuberculosis infection typically involves a combination of antibiotics, including isoniazid, rifampicin, and pyrazinamide, as developed by Selman Waksman and Gerhard Domagk. University of Pennsylvania and Columbia University have been investigating the use of new drugs and drug regimens to improve the treatment of TB, including the use of bedaquiline and delamanid. National Institute of Allergy and Infectious Diseases (NIAID) and CDC have been working to combat the spread of drug-resistant TB, including multidrug-resistant TB and extensively drug-resistant TB, as seen in Europe and North America. European Centre for Disease Prevention and Control (ECDC) and WHO have been supporting the development of new treatment guidelines and public health strategies to control the spread of TB.

● Epidemiology

Mycobacterium tuberculosis is a major public health problem worldwide, with an estimated 2 billion people infected with the bacterium, according to WHO and CDC. The bacterium is responsible for approximately 1.5 million deaths per year, making it one of the leading causes of death from a single infectious agent, as noted by University of London and University of Tokyo. Harvard School of Public Health and University of California, Los Angeles (UCLA) have been studying the epidemiology of TB, including the role of social determinants and health disparities in the spread of the disease, as seen in Africa and Asia. United States Agency for International Development (USAID) and Global Fund to Fight AIDS, Tuberculosis and Malaria have been supporting efforts to control the spread of TB, including the development of new vaccines and treatment strategies. Category:Tuberculosis